EUCTR2004-001246-33-IT进行中（未招募）不适用
An open label trial of TMC114/RTV in HIV-1 infected subjects who were randomized in the trials TMC114-C201 or TMC114-C207.
TIBOTEC PHARMACEUTICALS LTD.0 个研究点开始时间: 2005年4月14日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
An open label trial of TMC114/RTV in HIV-1 infected subjects who were randomized in the trials TMC114-C201, TMC114-C207 or in sponsor selected Phase I trials. - TMC114-C208EUCTR2004-001246-33-GBTibotec Pharmaceuticals Limited Ireland89
进行中（未招募）
不适用
An open label trial of TMC114/RTV in HIV-1 infected subjects who were randomized in the trials TMC114-C201, TMC114-C207 or in sponsor selected Phase I trials. - TMC114-C208HIV-1 infectionMedDRA version: 9.1Level: LLTClassification code 10020161Term: HIV infectionEUCTR2004-001246-33-DKTibotec Pharmaceuticals Ltd. Ireland89
进行中（未招募）
不适用
An open label trial of TMC114/RTV in HIV-1 infected subjects who were randomized in the trials TMC114-C201, TMC114-C207 or in sponsor selected Phase I trials. - TMC114-C208HIV-1 infectionMedDRA version: 9.1Level: LLTClassification code 10020161Term: HIV infectionEUCTR2004-001246-33-ATTibotec Pharmaceuticals Limited Ireland89
进行中（未招募）
不适用
An open-label trial with TMC125 in HIV-1 infected subjects, who were randomized to a TMC125 treatment arm in a sponsor-selected TMC125 trial and were treated for at least 48 weeks. - N/AHIV-1 InfectionMedDRA version: 9.1Level: LLTClassification code 10020192Term: HIV-1EUCTR2005-000712-27-DETibotec Pharmaceuticals Limited300
进行中（未招募）
不适用
An open-label trial with TMC125 in HIV-1 infected subjects, who were randomized to a TMC125 treatment arm in a sponsor-selected TMC125 trial and were treated for at least 48 weeks.EUCTR2005-000712-27-ITTIBOTEC PHARMACEUTICALS LTD.